Feedback PLC Partnership with Amazon Web Services (3521V)
13 December 2021 - 6:00PM
UK Regulatory
TIDMFDBK
RNS Number : 3521V
Feedback PLC
13 December 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR"). With the publication of this announcement,
this information is now considered to be in the public domain.
Feedback plc
Feedback receives funding from Amazon Web Services in support of
its cloud-based tuberculosis screening programme for rural
communities in India
-- AWS provides non-equity funding to support the initial
hosting costs of a pilot for Feedback's cloud-based tuberculosis
("TB") screening solution to rural communities in India
-- The TB screening solution will see X-ray images acquired in
rural communities pushed by Feedback's Bleepa Box straight to the
cloud to be processed by clinical and artificial intelligence
("AI") partners
-- The TB screening pathway, hosted on Bleepa, will connect
remote communities with clinical experts and the latest
technologies for point of care diagnosis of TB in almost any
setting and will be hosted on AWS Cloud
London, 13 December 2021 : Feedback plc (AIM: FDBK, "Feedback"
or the "Company"), the specialist clinical communication company,
announces that it has partnered with Amazon Web Services (AWS) to
establish and deliver cloud-based TB screening services to rural
communities in India.
Feedback has been awarded funding through the AWS Diagnostic
Development Initiative to deliver a revolutionary imaging pathway
that will enable X-rays of patients to be acquired in rural
settings without networked connectivity and be transmitted over
Bleepa's cloud-hosted infrastructure for reporting. This pathway
will enable TB screening to be undertaken in even the most remote
setting, ensuring diagnostic input is rapidly available to
screening services whilst the patient is still in the X-ray clinic.
This rapid, point-of-care diagnostic service leverages the power of
cloud to ensure that TB screening can be scaled to rural locations
across India.
The AWS Diagnostics Development Initiative aims to help
accelerate research and innovation to advance the collective
understanding and detection of infectious diseases in order to
mitigate current and future outbreaks. The funding is targeted at
covering the initial cloud hosting costs of the TB screening
service in the pilot stages, ahead of plans to scale the service
across India following a successful pilot .
TB represents a large public health issue globally with India
experiencing an estimated 2.6m new cases every year. A robust
screening programme, delivered locally to citizens is essential in
order to identify those affected and initiate treatment for the
condition. Chest X-rays are a key screening investigation for TB
but require interpretation by either a specialist clinician or
suitably regulated AI technology, neither of which are available in
most rural settings.
Feedback's technology enables a chest X-ray image to be pushed
over a mobile network to the cloud where it is shared by Bleepa
either with a specialist clinician for reporting or a suitable AI
tool, the results then being shared through Bleepa with the TB
screening service, often within minutes of an image being acquired.
Specialist TB clinicians can then advise on management, using
Bleepa's patient-specific chat feature to connect directly to TB
screening personnel in order to initiate treatment whilst the
patient is still in the vicinity. The image and any clinical
reports or discussion will then be stored in a CareLocker - a cloud
container that stores medical data at an individual patient level -
for every patient, which could enable the creation of citizen
health records in line with the National Digital Health Mission
record ("NDHM") of the Indian government. The entire solution will
be hosted on AWS cloud.
Dr Tom Oakley, CEO of Feedback, said: "We are delighted to have
AWS as a partner in our TB screening programme. This funding
support will enable us to establish and subsequently scale the TB
screening solution to citizens in rural locations across India. It
is a key public health priority and a challenge of enormous
proportions. To have AWS support and backing will make all the
difference in getting this out to the citizens who need it."
"Cloud-powered diagnostic tools are critical in the fight
against turberculosis and other infectious diseases said Maggie
Carter, Global Lead, Social Impact at AWS. "Over the last year, AWS
has seen inspirational results from the Diagnostic Development
Initiative. We look forward to helping Bleepa and other
organizations worldwide use the cloud to mitigate current and
future infectious disease outbreaks."
Further information on Bleepa can be found on the Company's
website:
https://fbkmed.com/feedback-plc/reports-and-presentations/
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Anesh Patel, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas 07980 541 893 or 07748 325 236
Johnson or 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical
communication products. Its core product, Bleepa, is a
revolutionary medical imaging communications app, providing an
easy-to-use, high quality tool to enable remote and secure
communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging
communications platform on the NHSx clinical communications tools
framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care providers. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of clinical
review.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAEAEFLFFFAA
(END) Dow Jones Newswires
December 13, 2021 02:00 ET (07:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2024 to Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Jul 2023 to Jul 2024